On July 28, Gilead Sciences rose 3.13% in regular trading, trading at approximately $135.53/share, with turnover of $2.49 billion. The gain was driven by broad-based strength across the biotechnology sector combined with growing optimism ahead of the company's quarterly earnings report scheduled for August 4.

The biotech sector saw notable gains on the session, with Amgen up 5.57%, Incyte up 5.09%, AbbVie up 3.58%, Alnylam Pharmaceuticals up 3.44%, and Vertex Pharmaceuticals up 2.62%, indicating strong sector-wide momentum. Market consensus expects Gilead's quarterly revenue to grow approximately 6.13% year-over-year, with institutional sentiment leaning bullish.

On the catalyst front, the EMA's CHMP recently recommended marketing authorization for Trodelvy in combination with Keytruda for first-line PD-L1-positive metastatic triple-negative breast cancer, reinforcing product expansion expectations. Additionally, Trodelvy previously received FDA approval for first-line advanced triple-negative breast cancer, further strengthening commercial momentum in the oncology pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)